The Label Wanted a Pop Princess (but She Wanted to Rock Out): This Flawed Debut Is Now an Alternative Cult Classic - Ultimate Guitar

FDA approves Alhemo® as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B (HA/HB) without inhibitors – PR Newswire

August 1, 2025

FDA approves Alhemo® as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B (HA/HB) without inhibitors PR NewswireAlhemo®’s FDA Approval for Hemophilia A/B Without Inhibitors: A Game-Changer for Novo Nordisk’s Rare Disease Portfolio AInvestEuropean Medicines Agency Issues Positive Opinion for Concizumab Label Update in Hemophilia Docwire NewsNovo Nordisk (NVO) Gains Positive CHMP Nod for Alhemo Label Expa GuruFocusNovo Nordisk’s Alhemo Recommended for Expanded Use in Europe for Haemophilia A and B Insider Monkey